CTAD 2025 | Diagnostic performance of novel plasma assays for detecting AD pathology across the disease spectrum

Charlotte Teunissen, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands, comments on the diagnostic performance of novel plasma assays for detecting amyloid pathology across the Alzheimer’s disease (AD) spectrum. Prof. Teunissen highlights that the assays, including pTau217, Aβ42 and Aβ40, showed high analytical performance and excellent diagnostic accuracy, with the HISCL-5000 pTau217 assay demonstrating the best discriminative value for distinguishing AD from controls. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.